Skip to main content
OpenTrials
Completed

NCT Number: NCT01545271

Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth

This study examines the effect of inhaled xenon gas in the treatment of newborn infants with hypoxic-ischemic encephalopathy (HIE) in combination with cooling, which is the standard treatment for this condition. The hypothesis is that the xenon + cooling combination will produce better neuroprotection than the standard treatment of cooling alone.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Infants will be eligible for for the trial if the St Michael's hospital standard inclusion criteria for cooling and additional inclusion criteria for xenon administration are met.

St Michael's hospital standard inclusion criteria for standard hypothermia treatment of 72 hrs:

A: Neonates born at greater than 36 weeks gestation (estimated or clinical assessment) with at least ONE of the following:

  • Apgar score of ≤5 at ten minutes after birth
  • Continued need for resuscitation, including tracheal or mask ventilation, at ten minutes after birth
  • Acidosis, defined as either umbilical cord pH or any arterial, venous or capillary pH within 60 minutes of birth less < 7.00
  • Base deficit ≥16 mmol/L in umbilical cord blood sample or any blood sample within 60 minutes of birth (arterial or venous blood).

If the infant meets criterion A then assess for neurological abnormality using criterion B and C (by trained personnel):

B: Moderate or Severe encephalopathy as evidenced by any of the following:

  • Altered state of consciousness (reduced or absent responses or pathological irritability and hyper responsive and at least ONE or more of the following:
  • Hypotonia
  • Abnormal reflexes including oculomotor or pupillary abnormalities
  • Absent or weak suck
  • Clinical seizures, as recorded by trained personnel

And

C: At least 30 minutes duration of amplitude-integrated electroencephalography (aEEG) recording that shows abnormal background aEEG activity. The decision to cool is based on the worst 30 min section of the aEEG, not the best [35] or seizures (clinical or electrical) thus meeting ONE of the following:

  • Normal background with some (> 5 min) electrical seizure activity
  • Moderately abnormal activity (upper margin of trace >10μV and lower margin <5μV)
  • Suppressed activity (upper margin of trace <10μV and lower margin of trace <5μV)
  • Definite seizure activity

Additional inclusion criteria for xenon:

Before being considered for additional inhaled xenon therapy via the breathing gas mixture, the infant would need to meet further additional entry criteria (all must be met):

  • Intubated, ventilated, sedated, being cooled
  • ≤ 5 hours old
  • Any seizures under control
  • Weight > 2nd centile for gestational age
  • Stable cardiovascular parameters; Mean arterial pressure >40mmHg.
  • Oxygen requirement via mechanical ventilator ≤ 40%.
  • Positive End Expiratory Pressure (PEEP) requirement ≤ 6cm H2O
  • Arterial pCO2 within acceptable range (<7kPa)
  • Absence of major congenital abnormalities, imperforate anus and in particular any bowel obstruction, congenital abnormalities suggestive of chromosomal anomaly or other syndromes that include brain dysgenesis. Congenital syndromes affecting the brain should be excluded when diagnosed.

Exclusion criteria

for cooling in the CoolXenon2 study

  • Infants expected to be greater than 3 hours of age at the time of starting cooling treatment.
  • Futility. Where prognosis is considered to be hopeless e.g. no cardiac output for 20 minutes.

Treatment and study plan

xenon gas

Drug

Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.

Other names: LENOXe

Whole body cooling

Device

Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.

Primary outcomes

  1. Death and moderate or severe disability - Bayley III

    Time frame: at 18 months of age

    Bayley Scales of Infant and Toddler Development III (Bayley III) has three domains: cognition, language and motor skills. Each domain is based on a series of examinations of different severity. The lower cut off level is 55 for cognition, 47 for language and 46 for motor. The upper value can be 145. Assessment of hearing and vision: severe hearing loss defined as inability to hear without amplification; severe visual loss defined as being unable to move independently.

Secondary outcomes

  1. Brain MRI

    Time frame: less than 2 weeks of age

    Magnetic Resonance Imaging findings at less than 2 weeks of age

  2. Amplitude Integrated Electroencephalogram (aEEG) grading

    Time frame: Before hospital discharge; usually within one week of birth

    Number of hours after birth when aEEG voltage has reached a normal or discontinuous normal pattern

Other outcomes

  1. Number of normal infants

    Time frame: 18-24 months

    Bayley III composite score ≥ 85 and no neurosensory disability as described above

Sponsors and collaborators

Lead sponsor

University Hospitals Bristol and Weston NHS Foundation Trust

Other

Collaborators

  • University of Bristol

Registry information

Official study title

Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A Randomised Pilot Study

Acronym: CoolXenon2

Important dates

Study start
2012
Primary completion
2013
Study completion
2015
First posted
Mar 6, 2012
Registry last updated
Dec 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.